Is Piramal Pharma a Good Buy After Its Q1 FY27 Results?

September 4, 2026
Posted by: Kunal Singla
Category: Market

Piramal Pharma share price around Rs 214. 3.0% below 52-week high of Rs 220. Q1 FY27 revenue Rs 2,359 crore, up 18.4% YoY. loss of Rs 69 crore.

Quick Answer

Piramal Pharma continued to report a net loss in Q1 FY27, at Rs 69 crore, though the loss narrowed year on year as revenue grew to Rs 2,359 crore. The Piramal Pharma share price near Rs 214 reflects a business still working toward profitability, so this is best treated as a turnaround watch rather than a value buy on this quarter’s numbers.

The Piramal Pharma share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Piramal Pharma is a pharmaceutical company with CDMO, complex hospital generics and consumer healthcare businesses, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.

Revenue for the quarter came in at Rs 2,359 crore, up 18.4% year on year, while the company reported a net loss of Rs 69 crore. That combination of numbers is exactly what this article breaks down, along with what it means for the Piramal Pharma share price from here.

This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Piramal Pharma share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.

Click Here – Get Free Investment Predictions

Table of Contents

Piramal Pharma Q1 FY27 Financial Highlights

Metric	Q1 FY27	Q1 FY26	YoY Change
Revenue	Rs 2,359 crore	Rs 1,992 crore	18.4%
EBITDA	Rs 285 crore	Rs 165 crore	72.4%
Operating Margin	13.4%	10.6%	NA
Profit Before Tax	-Rs 7.46 crore	-Rs 79 crore	90.6%
Net Profit / (Loss)	-Rs 69 crore	-Rs 82 crore	15.1%

Piramal Pharma Q1 FY27 Performance Analysis

Check Piramal Pharma Fundamentals on Univest Screener

Revenue growth of 18.4% for the quarter came from steady demand across the company’s core business, keeping the topline trend intact for the pharmaceuticals and CDMO services sector.

The loss for the quarter came in narrower year on year at -Rs 69 crore, against -Rs 82 crore a year ago. Revenue grew 18.4% in the same period, so the business is scaling, but profitability has not yet followed, which is the central issue for anyone tracking the Piramal Pharma share price for a turnaround.

On a sequential basis, revenue moved down 15.7% sequentially from Rs 2,798 crore in the March 2026 quarter and the net loss moved down 685.8% sequentially from -Rs 8.83 crore in the prior quarter, giving a fuller picture of the trend behind the Piramal Pharma share price than the year on year comparison alone.

Key Business Factors in Q1 FY27

Revenue Trend

Piramal Pharma’s revenue grew 18.4% year on year this quarter, taking the quarterly base to Rs 2,359 crore in a pharmaceuticals and CDMO services business that remains sensitive to demand and pricing cycles that ultimately feed through to the Piramal Pharma share price.

Margin Movement

EBITDA rose 72.4% to Rs 285 crore, and operating margin moved to 13.4% from 10.6% a year earlier, a sign that cost control or pricing held up during the quarter.

Balance Sheet Position

Piramal Pharma’s debt-to-equity ratio stands at 0.70, a level worth monitoring given the quarter’s margin trend.

Valuation Context

Piramal Pharma does not carry a meaningful PE multiple this quarter given its current earnings, so investors should lean on revenue and book value trends instead of the price-to-earnings ratio when assessing the Piramal Pharma share price.

Dividend Details

No interim dividend was declared alongside Piramal Pharma’s Q1 FY27 results. The stock has not paid a meaningful dividend in the trailing twelve months. Investors tracking the Piramal Pharma share price for income should watch the company’s announcements around its next annual results for any dividend decision.

Piramal Pharma Share Price Outlook for FY27

Piramal Pharma remains a turnaround story rather than a steady compounder for now. Revenue growth is encouraging, but the pace at which losses shrink over the coming quarters will matter more to the Piramal Pharma share price than the topline trend alone.

A clear, sustained narrowing of losses over the next two to three quarters would be the strongest signal for the Piramal Pharma share price, while a stall or reversal in that trend would call for more caution.

Piramal Pharma Stock Performance

Download the Univest iOS App or Univest Android App to track Piramal Pharma’s live share price and get daily stock updates.

The Piramal Pharma share price was trading around Rs 214 as results season played out in late August 2026, roughly 3.0% below its 52-week high of Rs 220 and well above its 52-week low of Rs 132. Promoter holding stood at 34.8% as of the June 2026 quarter.

The Piramal Pharma share price has moved without much drama on this result, consistent with a quarter that did not materially change the investment case either way. On profitability ratios, the company reports a return on equity of -3.58% and a book value of around Rs 61 per share, both useful reference points when judging whether the current price is reasonable.

Key Risks

Profitability Risk

The quarter’s profit trend is the clearest risk here. Until Piramal Pharma shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results.

Leverage Risk

A debt-to-equity ratio of 0.70 means the company’s earnings are more sensitive to interest rate and refinancing conditions than a lower-debt peer.

Sector and Demand Risk

As a pharmaceuticals and CDMO services business, Piramal Pharma’s results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Piramal Pharma share price well before the next result.

Conclusion

Piramal Pharma remains loss-making in Q1 FY27, with the loss narrowing year on year alongside revenue growth of 18.4%. The Piramal Pharma share price suits investors comfortable with a turnaround story more than those looking for near-term profitability, and position sizing should reflect that risk.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Piramal Pharma Q1 FY27 Results

What were Piramal Pharma’s Q1 FY27 results?

Ans. Piramal Pharma reported Q1 FY27 revenue of Rs 2,359 crore, up 18.4% year on year, with a net loss of Rs 69 crore.

Is Piramal Pharma a good buy after its Q1 FY27 results?

Ans. Piramal Pharma’s profitability came under pressure this quarter, which makes this a stock to watch rather than an obvious buy purely on this result. Investors should form their own view based on their own risk appetite and time horizon.

What is the Piramal Pharma share price today?

Ans. The Piramal Pharma share price was trading around Rs 214 in late August 2026, about 3.0% below its 52-week high of Rs 220 and well above its 52-week low of Rs 132.

What is Piramal Pharma’s revenue and profit for Q1 FY27?

Ans. Piramal Pharma reported revenue of Rs 2,359 crore and a net loss of Rs 69 crore for the quarter ended June 30, 2026.

Did Piramal Pharma declare a dividend with its Q1 FY27 results?

Ans. No interim dividend was declared alongside Piramal Pharma’s Q1 FY27 results. Investors should track the company’s next annual results for any dividend announcement.

Why does Piramal Pharma not have a meaningful PE ratio?

Ans. Piramal Pharma does not carry a meaningful price-to-earnings ratio currently because of its recent earnings performance. Investors should use revenue and book value trends instead when assessing the stock.

What are the key risks for Piramal Pharma investors right now?

Ans. The quarter’s profit trend is the clearest risk here. Until Piramal Pharma shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results. As a pharmaceuticals and CDMO services business, Piramal Pharma’s results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Piramal Pharma share price well before the next result.

What is Piramal Pharma’s promoter shareholding?

Ans. Promoter holding in Piramal Pharma stood at 34.8% as of the June 2026 quarter.

News

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.